GuidelinePloS one2023

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France.

Loïg Gaugain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.